| 3,3 diindolylmethane |
NCT02197000 |
Unknown status |
Not Applicable |
A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers |
BRCA1 Gene Mutation|BRCA2 Gene Mutation |
https://ClinicalTrials.gov/show/NCT02197000 |
| 3,3 diindolylmethane |
NCT00888654 |
Completed |
Phase 2 |
Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy |
Prostate Cancer |
https://ClinicalTrials.gov/show/NCT00888654 |
| 3,3 diindolylmethane |
NCT02525159 |
Completed |
Phase 3 |
Effectiveness of DIM Supplements to Increase 2-OHE1/16 Ratio |
Breast Cancer |
https://ClinicalTrials.gov/show/NCT02525159 |
| 3,3 diindolylmethane |
NCT02483624 |
Terminated |
Phase 1 |
3,3'-Diindolylmethane in Patients With Systemic Lupus Erythematosus |
SLE |
https://ClinicalTrials.gov/show/NCT02483624 |
| 3,3 diindolylmethane |
NCT00784394 |
Completed |
Phase 1 |
Diindolylmethane in Preventing Cancer in Healthy Volunteers |
Healthy, no Evidence of Disease |
https://ClinicalTrials.gov/show/NCT00784394 |
| 3,3 diindolylmethane |
NCT00392652 |
Completed |
Phase 1 |
Diindolylmethane in Healthy Volunteers |
Healthy, no Evidence of Disease |
https://ClinicalTrials.gov/show/NCT00392652 |
| 3,3 diindolylmethane |
NCT01391689 |
Completed |
Not Applicable |
Diindolylmethane in Treating Patients With Breast Cancer |
Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer |
https://ClinicalTrials.gov/show/NCT01391689 |
| 3,3 diindolylmethane |
NCT01022333 |
Unknown status |
Phase 1 |
The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers |
Breast Cancer |
https://ClinicalTrials.gov/show/NCT01022333 |
| 3,3 diindolylmethane |
NCT00450229 |
Completed |
Phase 1 |
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer |
Adenocarcinoma of the Prostate|Prostate Cancer|Stage I Prostate Cancer|Stage II Prostate Cancer |
https://ClinicalTrials.gov/show/NCT00450229 |
| 3,3 diindolylmethane |
NCT00212381 |
Completed |
Phase 3 |
Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia |
Cervical Dysplasia |
https://ClinicalTrials.gov/show/NCT00212381 |
| 3,3 diindolylmethane |
NCT00462813 |
Completed |
Phase 3 |
Diindolylmethane in Treating Patients With Abnormal Cervical Cells |
Cervical Cancer|Precancerous Condition |
https://ClinicalTrials.gov/show/NCT00462813 |
| 3,3 diindolylmethane |
NCT00591305 |
Terminated |
Not Applicable |
New Therapy of Laryngeal Papilloma In Children |
Papilloma |
https://ClinicalTrials.gov/show/NCT00591305 |
| 3,3 diindolylmethane |
NCT03152097 |
Completed |
Not Applicable |
Targeting FMO-Mediated TMAO Formation in Kidney Disease (TMAO) Study |
Kidney Diseases|Cardiovascular Diseases |
https://ClinicalTrials.gov/show/NCT03152097 |
| 3,3 diindolylmethane |
NCT01612910 |
Withdrawn |
Phase 2 |
Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery |
Breast Cancer Female |
https://ClinicalTrials.gov/show/NCT01612910 |
| 3,3 diindolylmethane |
NCT01846364 |
Terminated |
Early Phase 1 |
DIM as a Treatment for Thyroid Disease |
Proliferative Thyroid Disease |
https://ClinicalTrials.gov/show/NCT01846364 |
| 3,3 diindolylmethane |
NCT00305747 |
Completed |
Phase 1 |
Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy |
Prostate Cancer |
https://ClinicalTrials.gov/show/NCT00305747 |
| 3,3 diindolylmethane |
NCT03802721 |
Recruiting |
Early Phase 1 |
Pharmacokinetics of Benzo[a]Pyrene: Impact of Diet |
Environmental Exposure |
https://ClinicalTrials.gov/show/NCT03802721 |
| 3,3 diindolylmethane |
NCT04292236 |
Completed |
N/A |
The Effect of Food Supplements on Food Intake and Gut Hormone Levels |
Obesity|Endocrine |
N/A |
| Atiprimod |
NCT00430014 |
Terminated |
Phase 1 |
Study of Atiprimod Treatment for Patients With Advanced Cancer |
Advanced Cancer |
https://ClinicalTrials.gov/show/NCT00430014 |
| Atiprimod |
NCT00214838 |
Unknown status |
Phase 1|Phase 2 |
An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer |
Advanced Cancer |
https://ClinicalTrials.gov/show/NCT00214838 |
| Atiprimod |
NCT00388063 |
Completed |
Phase 2 |
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma |
Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT00388063 |
| Atiprimod |
NCT00663429 |
Completed |
Phase 2 |
Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma |
Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT00663429 |
| Atiprimod |
NCT00086216 |
Completed |
Phase 1|Phase 2 |
Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma |
Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00086216 |
| Auranofin |
NCT02176135 |
Withdrawn |
Phase 1|Phase 2 |
Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection |
HIV |
https://ClinicalTrials.gov/show/NCT02176135 |
| Auranofin |
NCT02089048 |
Completed |
Phase 1 |
Auranofin PK Following Oral Dose Administration |
Amoebiasis |
https://ClinicalTrials.gov/show/NCT02089048 |
| Auranofin |
NCT01747798 |
Completed |
Early Phase 1 |
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
Recurrent Fallopian Tube Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Primary Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT01747798 |
| Auranofin |
NCT01419691 |
Completed |
Phase 2 |
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) |
Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma|Leukemia, Prolymphocytic |
https://ClinicalTrials.gov/show/NCT01419691 |
| Auranofin |
NCT03456700 |
Active, not recruiting |
Phase 2 |
Auranofin and Sirolimus in Treating Participants With Ovarian Cancer |
Ovarian Serous Tumor|Recurrent Ovarian Carcinoma |
https://ClinicalTrials.gov/show/NCT03456700 |
| Auranofin |
NCT02736968 |
Recruiting |
Phase 2 |
Auranofin for Giardia Protozoa |
Amoebic Dysentery|Giardiasis |
https://ClinicalTrials.gov/show/NCT02736968 |
| Auranofin |
NCT02063698 |
Completed |
Phase 2 |
Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome |
Pain |
https://ClinicalTrials.gov/show/NCT02063698 |
| Auranofin |
NCT02126527 |
Withdrawn |
Phase 1 |
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer |
Recurrent Non-small Cell Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific |
https://ClinicalTrials.gov/show/NCT02126527 |
| Auranofin |
NCT01737502 |
Recruiting |
Phase 1|Phase 2 |
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer |
Extensive Stage Small Cell Lung Carcinoma|Lung Adenocarcinoma|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Small Cell Lung Carcinoma|Squamous Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT01737502 |
| Auranofin |
NCT02961829 |
Active, not recruiting |
Not Applicable |
Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure |
Chronic Infection|HIV |
https://ClinicalTrials.gov/show/NCT02961829 |
| Auranofin |
NCT02968927 |
Active, not recruiting |
Phase 2 |
TB Host Directed Therapy |
Tuberculosis |
https://ClinicalTrials.gov/show/NCT02968927 |
| Auranofin |
NCT02770378 |
Active, not recruiting |
Phase 1|Phase 2 |
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma |
Glioblastoma |
https://ClinicalTrials.gov/show/NCT02770378 |
| Auranofin |
NCT03975790 |
Completed |
N/A |
Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX |
Rheumatoid Arthritis |
https://ClinicalTrials.gov/show/NCT03975790 |
| Auranofin |
NCT01557348 |
Completed |
N/A |
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor |
Rheumatoid Arthritis |
https://ClinicalTrials.gov/show/NCT01557348 |
| AZD1480 |
NCT01219543 |
Terminated |
Phase 1 |
A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase. |
Solid Tumour|Advanced Solid Malignancies|Child-Pugh A to B7 Advanced Hepatocellular Carcinoma|EGFR and/or ROS Mutant NSCLC|Lung Metastasis Carcinoma|Gastric Cancer |
https://ClinicalTrials.gov/show/NCT01219543 |
| AZD1480 |
NCT01112397 |
Terminated |
Phase 1 |
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours |
Solid Malignancies |
https://ClinicalTrials.gov/show/NCT01112397 |
| AZD1480 |
NCT00910728 |
Completed |
Phase 1 |
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases |
Primary Myelofibrosis (PMF)|Post-Polycythaemia Vera|Essential Thrombocythaemia Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00910728 |
| Capsaicin |
NCT03317613 |
Recruiting |
Phase 2 |
Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain |
Neuropathic Pain |
https://ClinicalTrials.gov/show/NCT03317613 |
| Capsaicin |
NCT04125563 |
Recruiting |
Phase 2 |
Influence on Cough and Airway Symptoms by Oral Capsaicin |
Cough |
https://ClinicalTrials.gov/show/NCT04125563 |
| Capsaicin |
NCT04283292 |
Not yet recruiting |
Phase 4 |
Capsaicin for the Treatment of Cannabinoid Hyperemesis Syndrome |
Cannabinoid Hyperemesis Syndrome |
https://ClinicalTrials.gov/show/NCT04283292 |
| Capsaicin |
NCT02441660 |
Recruiting |
Not Applicable |
Capsaicin 8% Patch for Spinal Cord Injury Neuropathic Pain |
Spinal Cord Injuries|Neuropathic Pain |
https://ClinicalTrials.gov/show/NCT02441660 |
| Capsaicin |
NCT03899246 |
Active, not recruiting |
Phase 1 |
Sickle Cell Pain: Intervention With Capsaicin Exposure |
Neuropathic Pain|Sickle Cell Disease |
https://ClinicalTrials.gov/show/NCT03899246 |
| Capsaicin |
NCT02037464 |
Unknown status |
Phase 2 |
CAPSAICIN Trial: Assessing Capsaicin as a Chemopreventive Agent for Prostate Cancer |
Prostate Cancer |
https://ClinicalTrials.gov/show/NCT02037464 |
| Capsaicin |
NCT02603783 |
Completed |
Not Applicable |
Esophageal capsaĂŻcin Infusion and Mucosal Integrity |
TRPV1 Protein, Human|Capsaicin|Electric Impedance|Esophagus|Intracellular Space|Pain Measurement|Microscopy, Electron |
https://ClinicalTrials.gov/show/NCT02603783 |
| Capsaicin |
NCT02570841 |
Completed |
Phase 4 |
Pain Thresholds Under High-dose Topical Capsaicin |
Pain |
https://ClinicalTrials.gov/show/NCT02570841 |
| Capsaicin |
NCT02346903 |
Unknown status |
Not Applicable |
Chest Pain Perception and Capsaicin Sensitivity |
Chest Pain |
https://ClinicalTrials.gov/show/NCT02346903 |
| Capsaicin |
NCT02346916 |
Unknown status |
Not Applicable |
Chest Pain Perception and Capsaicin Sensitivity in Patients With Acute Cardiac Ischemia |
Chest Pain |
https://ClinicalTrials.gov/show/NCT02346916 |
